KEYTRUDA® (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award


October 28, 2015 8:00 am ET

Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1
therapy for the treatment of advanced melanoma and metastatic non-small
cell lung cancer in patients whose disease has progressed after other
therapies, received the Prix Galien USA 2015 Award for Best
Biotechnology Product.

“As a company built on a foundation of scientific excellence, Merck is
honored to again have been chosen as a recipient of this prestigious
award,” said Dr. Roger M. Perlmutter, president, Merck Research
Laboratories. “This achievement is a testament to the remarkable
contributions of everyone at Merck, as well as the many physicians and
patients who participated in our clinical trials, in helping to bring
KEYTRUDA to patients.”

The Prix Galien Award recognizes the pharmaceutical industry’s
outstanding achievement in the development of new medicines. An
internationally recognized award, the Prix Galien was founded in France
in 1969 by French pharmacist Roland Mehl and is considered the highest
accolade for pharmaceutical research and development.

This latest award for KEYTRUDA is Merck’s seventh Prix Galien USA award
in nine years. The company was previously recognized for ZOSTAVAX
(2013), VICTRELIS (2012), ROTATEQ (2010), ISENTRESS (2008) and JANUVIA
and GARDASIL (2007). In total, around the world, Merck has won the Prix
Galien 40 times, making Merck the most-awarded company of all time.

About Merck

Today’s Merck is a global health care leader working to help the world
be well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies and
animal health products, we work with customers and operate in more than
140 countries to deliver innovative health solutions. We also
demonstrate our commitment to increasing access to health care through
far-reaching policies, programs and partnerships. For more information,
and connect with us on Twitter,
and YouTube.

Forward-Looking Statement of Merck & Co. Inc., Kenilworth, NJ, USA

This news release of Merck & Co., Inc., Kenilworth, NJ, USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities
Litigation Reform Act of 1995. These statements are based upon the
current beliefs and expectations of the company’s management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.

Risks and uncertainties include, but are not limited to, general
industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and healthcare legislation in the
United States and internationally; global trends toward healthcare cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2014 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (

Pamela Eisele, 267-305-3558

Unsubscribe from email alerts